TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Oncology

Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer

Key Statistics

  • 70% — Advanced-stage relapse after 1ST-line chemo
  • ~50% — HGSC with HRD (TCGA)
  • 20% — HGSC with BRCA1/2mut (TCGA)

Don't-miss facts

  1. 70% advanced ovarian cancer relapse rate after first-line chemo response is the rationale for maintenance therapy

  2. PARPi mechanism = PARP trapping + synthetic lethality; BRCA1/2mut/HRD tumours respond best

  3. Three approved PARPi: olaparib, niraparib, rucaparib. Olaparib first-line up to 2 yrs (+bevacizumab 15 mo); niraparib up to 3 yrs

  4. MyChoice® HRD-positive GIS cut-off = 42 (PAOLA-1/PRIMA); VELIA used 33

  5. PAOLA-1: olaparib+bevacizumab gives no benefit if HRD-negative (HR 1.0) – NICE/FDA/EMA restrict combo to HRD+/BRCA1/2mut

  6. SOLO-1 5-yr PFS: 56 vs 13.8 months (olaparib vs placebo, BRCA1/2mut, HR 0.33)

  7. PARPi ↑ severe AEs (RR 2.62) & MDS/AML risk (OR 2.63) – balance against PFS gain using QA-PFS/Q-TWIST

  8. Mandatory consent for germline BRCA1/2 blood testing; tissue testing consent is good practice but not obligatory

HRD testing routes

BRCA1/2 mutation (germline/tumour) Non-BRCA HRR gene mutation (~30%)

Epigenomic silencing (BRCA1/RAD51C methylation) Genomic scar (GIS – MyChoice®/FoundationFocus®)

Mutational signature (SBS3) Functional (RAD51) – not clinic-ready

Abbreviation Key

  • HGSC — high-grade serous carcinoma
  • LOH/LST/TAI — loss of heterozygosity / large-scale transitions / telomeric allelic imbalance
  • HRD — homologous recombination deficiency
  • SBS — single-base substitution (mutational signature)
  • HRR — homologous recombination repair
  • PFS/OS — progression-free/overall survival
  • PARP/PARPi — poly-ADP-ribose polymerase / PARP inhibitor
  • HR — hazard ratio
  • BRCA1/2mut — BRCA1/2 mutation
  • PSROC — platinum-sensitive relapsed ovarian cancer
  • gBRCA/sBRCA/tBRCA — germline/somatic/tumour BRCA mutation
  • NMRD — no macroscopic residual disease
  • TCGA — The Cancer Genome Atlas
  • NICE — National Institute for Health and Care Excellence
  • DDR — DNA damage response
  • CDF — Cancer Drugs Fund
  • SSB/DSB — single-/double-strand DNA break
  • EMA/FDA — European Medicines Agency / US Food and Drug
  • NHEJ — nonhomologous end-joining Administration
  • BER/NER/MMR — base excision/nucleotide excision/mismatch
  • GLH — Genomic Laboratory Hub repair
  • STIC — serous tubal intraepithelial carcinoma
  • GIS — genomic instability score
  • QoL/QA-PFS/Q-TWIST — quality of life / quality-adjusted
  • PFS / MDS/AML — myelodysplastic syndrome / acute myeloid leukaemia quality-adjusted time without symptoms of toxicity

Source: Darwish A et al. Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer. The Obstetrician & Gynaecologist 2023;25:220–228. doi:10.1111/tog.12880

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free